

Keisuke Hino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3974372/publications.pdf>

Version: 2024-02-01

98
papers

11,000
citations

126907

33
h-index

51608

86
g-index

100
all docs

100
docs citations

100
times ranked

20388
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Genome-wide association of IL28B with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C. <i>Nature Genetics</i> , 2009, 41, 1105-1109.	21.4	2,124
3	Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. <i>Hepatology Research</i> , 2016, 46, 951-963.	3.4	463
4	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. <i>Gut</i> , 2020, 69, 1492-1501.	12.1	411
5	Hepatitis C Virus-Induced Reactive Oxygen Species Raise Hepatic Iron Level in Mice by Reducing Hpcidin Transcription. <i>Gastroenterology</i> , 2008, 134, 226-238.	1.3	242
6	Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. <i>Hepatology</i> , 2006, 44, 326-334.	7.3	222
7	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 424-432.	8.1	216
8	Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 762-768.	2.0	191
9	Hepatic Iron Overload Induces Hepatocellular Carcinoma in Transgenic Mice Expressing the Hepatitis C Virus Polyprotein. <i>Gastroenterology</i> , 2006, 130, 2087-2098.	1.3	155
10	Association between <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2015, 50, 776-784.	5.1	141
11	Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean. <i>PLoS ONE</i> , 2012, 7, e39175.	2.5	137
12	Distribution of Hepatitis B Virus Genotypes among Patients with Chronic Infection in Japan Shifting toward an Increase of Genotype A. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1476-1483.	3.9	114
13	Genome-wide association study identified ITPA/DDRCK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. <i>Human Molecular Genetics</i> , 2011, 20, 3507-3516.	2.9	85
14	Fibroblast activation protein- α -expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. <i>BMC Gastroenterology</i> , 2015, 15, 109.	2.0	75
15	Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 115-134.	4.5	70
16	The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1853-1860.	3.9	68
17	Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. <i>Journal of Gastroenterology</i> , 2004, 39, 1069-1077.	5.1	64
18	Iron loss triggers mitophagy through induction of mitochondrial ferritin. <i>EMBO Reports</i> , 2020, 21, e50202.	4.5	64

#	ARTICLE	IF	CITATIONS
19	Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. <i>Journal of Medical Virology</i> , 2005, 77, 39-46.	5.0	60
20	Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. <i>Hepatology Research</i> , 2006, 36, 107-114.	3.4	60
21	Direct Cytopathic Effects of Particular Hepatitis B Virus Genotypes in Severe Combined Immunodeficiency Transgenic With Urokinase-Type Plasminogen Activator Mouse With Human Hepatocytes. <i>Gastroenterology</i> , 2009, 136, 652-662.e3.	1.3	56
22	Hepatitis C Virus Core Protein Suppresses Mitophagy by Interacting with Parkin in the Context of Mitochondrial Depolarization. <i>American Journal of Pathology</i> , 2014, 184, 3026-3039.	3.8	56
23	Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. <i>Hepatology</i> , 2018, 68, 848-858.	7.3	53
24	Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 58-68.	4.3	42
25	Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). <i>Hepatology Research</i> , 2010, 40, 347-368.	3.4	40
26	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , 2012, 13, 47.	2.1	40
27	New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia. <i>PLoS ONE</i> , 2014, 9, e86449.	2.5	40
28	Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. <i>Scientific Reports</i> , 2016, 6, 24767.	3.3	39
29	Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan. <i>Hepatology Research</i> , 2021, 51, 957-967.	3.4	39
30	Hepatitis C virus core protein inhibits deoxycholic acid-mediated apoptosis despite generating mitochondrial reactive oxygen species. <i>Journal of Gastroenterology</i> , 2006, 41, 257-268.	5.1	38
31	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 7958.	3.3	38
32	In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. <i>Journal of Gastroenterology</i> , 2005, 40, 617-624.	5.1	36
33	Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection. <i>Free Radical Biology and Medicine</i> , 2019, 133, 193-199.	2.9	34
34	Iron metabolic disorder in chronic hepatitis C: Mechanisms and relevance to hepatocarcinogenesis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 93-98.	2.8	33
35	A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice. <i>Liver International</i> , 2011, 31, 552-560.	3.9	31
36	First jejunal vein oriented mesenteric excision for pancreatoduodenectomy. <i>Journal of Gastroenterology</i> , 2013, 48, 989-995.	5.1	30

#	ARTICLE	IF	CITATIONS
37	Risk Factors for Survival and the Development of Hepatocellular Carcinoma in Patients with Primary Biliary Cirrhosis. <i>Internal Medicine</i> , 2013, 52, 1553-1559.	0.7	30
38	A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 3759-3769.	3.9	29
39	Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 739-762.	4.5	29
40	Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 206-206.	1.6	29
41	Stronger Neo-Minophagen C?, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein. <i>Liver International</i> , 2007, 27, 845-853.	3.9	28
42	Analysis of lymphoid follicles in liver of patients with chronic hepatitis C. <i>Liver</i> , 1992, 12, 387-391.	0.1	28
43	Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice. <i>Liver International</i> , 2010, 30, 683-692.	3.9	28
44	Iron and liver cancer: an inseparable connection. <i>FEBS Journal</i> , 2022, 289, 7810-7829.	4.7	27
45	TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 270-270.	1.6	25
46	Mitochondrial reactive oxygen species as a mystery voice in hepatitis C. <i>Hepatology Research</i> , 2014, 44, 123-132.	3.4	23
47	Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice. <i>Liver International</i> , 2015, 35, 1303-1314.	3.9	23
48	Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon α -2b and ribavirin. <i>Nutrition</i> , 2006, 22, 114-122.	2.4	20
49	Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication. <i>Liver International</i> , 2008, 28, 1158-1166.	3.9	20
50	Temperature-Related Effects of Adenosine Triphosphate-Activated Microglia on Pro-Inflammatory Factors. <i>Neurocritical Care</i> , 2012, 17, 293-300.	2.4	20
51	Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study. <i>Hepatic Medicine: Evidence and Research</i> , 2013, 5, 11.	2.5	20
52	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. <i>Liver Cancer</i> , 2019, 8, 505-519.	7.7	20
53	<i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2018, 48, 521-528.	3.4	19
54	Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 1305-1311.	2.8	17

#	ARTICLE	IF	CITATIONS
55	417â€²±-Tocopherol and ascorbic acid attenuates the ribavirin-induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1269-1275.	2.8	17
56	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0219412.	2.5	17
57	Assessment of hepatic fibrosis with superb microvascular imaging in hepatitis C virus-associated chronic liver diseases. <i>Hepatology Research</i> , 2017, 47, 593-597.	3.4	16
58	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. <i>Journal of Gastroenterology</i> , 2018, 53, 247-257.	5.1	15
59	A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0154676.	2.5	14
60	Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 417-417.	1.6	14
61	Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C. <i>Human Genetics</i> , 2015, 134, 279-289.	3.8	13
62	Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. <i>Anticancer Research</i> , 2014, 34, 3125-9.	1.1	13
63	Hepatitis B virus genotype G is an extremely rare genotype in Japan. <i>Hepatology Research</i> , 2004, 30, 199-203.	3.4	11
64	Focal Nodular Hyperplasia-Like Nodule with Reduced Expression of Organic Anion Transporter 1B3 in Alcoholic Liver Cirrhosis. <i>Internal Medicine</i> , 2011, 50, 1193-1199.	0.7	11
65	Molecular typing of Bartonella henselae DNA extracted from human clinical specimens and cat isolates in Japan. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 60, 44-48.	2.7	9
66	Emergent laparoscopic cholecystectomy for acute acalculous cholecystitis revisited. <i>Surgery Today</i> , 2016, 46, 309-312.	1.5	9
67	Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C. <i>PLoS ONE</i> , 2016, 11, e0164418.	2.5	9
68	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 454.	3.7	9
69	Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4017-4017.	1.6	8
70	Correlation of hepatitis C virus-mediated endoplasmic reticulum stress with autophagic flux impairment and hepatocarcinogenesis. <i>Medical Molecular Morphology</i> , 2021, 54, 108-121.	1.0	7
71	Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension. <i>Journal of Gastroenterology</i> , 2007, 42, 407-409.	5.1	6
72	Iron as Soul of Life on Earth Revisited: From Chemical Reaction, Ferroptosis to Therapeutics. <i>Free Radical Biology and Medicine</i> , 2019, 133, 1-2.	2.9	6

#	ARTICLE	IF	CITATIONS
73	Assessment criteria for sarcopenia in liver disease (first edition): Report from the working group for creation of sarcopenia assessment criteria in the Japan Society of Hepatology. <i>Acta Hepatologica Japonica</i> , 2016, 57, 353-368.	0.1	6
74	Clinical usefulness of non- α -protein respiratory quotient measurement in non- α -alcoholic fatty liver disease. <i>Hepatology Research</i> , 2013, 43, 1284-1294.	3.4	5
75	Acyl/free carnitine ratio is a risk factor for hepatic steatosis after pancreatoduodenectomy and total pancreatectomy. <i>Pancreatology</i> , 2017, 17, 135-138.	1.1	5
76	Long-term phlebotomy successfully alleviated hepatic iron accumulation in a ferroportin disease patient with a mutation in SLC40A1: a case report. <i>BMC Gastroenterology</i> , 2021, 21, 111.	2.0	5
77	Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines. <i>Scientific Reports</i> , 2021, 11, 3703.	3.3	5
78	Metal Metabolism and Liver. , 2016, , 123-146.		5
79	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. <i>Hepatology Research</i> , 2011, 41, 505-511.	3.4	4
80	Assessment of clinical and magnetic resonance imaging features of de novo hypervascular hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. <i>Hepatology Research</i> , 2017, 47, E152-E160.	3.4	4
81	Hepatic oxidative stress in ovariectomized transgenic mice expressing the hepatitis C virus polyprotein is augmented through suppression of adenosine monophosphate-activated protein kinase/proliferator-activated receptor gamma co-activator 1 alpha signaling. <i>Hepatology Research</i> , 2014, 44, E229-39.	3.4	3
82	Clinical predictor for development of hepatocellular carcinoma in patients with primary biliary cirrhosis. <i>Acta Hepatologica Japonica</i> , 2008, 49, 449-451.	0.1	3
83	Prevalence and outcomes of acute hepatitis B in Okayama, Japan, 2006-2010. <i>Acta Medica Okayama</i> , 2014, 68, 243-7.	0.2	2
84	3. Iron Metabolism Disorders and Iron Reduction Therapy in Patients with Chronic Liver Diseases.. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 1248-1254.	0.0	1
85	Iron metabolic disorder in chronic hepatitis C: insights from recent evidence. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 251-256.	0.8	1
86	L-Carnitine Supplementation Improved Hepatic Steatosis After Pancreatectomy. <i>Pancreas</i> , 2016, 45, e7-e9.	1.1	1
87	Assessment criteria for sarcopenia in liver disease (first edition): Report from the working group for creation of sarcopenia assessment criteria in the Japan Society of Hepatology. <i>Acta Hepatologica Japonica</i> , 2016, 57, 623-633.	0.1	1
88	Liver Cirrhosis with Inherited Liver Disease: Hemochromatosis. , 2019, , 47-57.		1
89	A follow-up survey of hepatitis virus carriers after notification of their infection in Okayama prefecture. <i>Acta Hepatologica Japonica</i> , 2013, 54, 84-86.	0.1	1
90	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C. <i>Acta Hepatologica Japonica</i> , 2009, 50, 665-677.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Type I interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. <i>Hepatic Medicine: Evidence and Research</i> , 2011, 3, 45.	2.5	0
92	Role of Oxidative Stress in Alcoholic/Non-Alcoholic Liver Diseases. , 2019, , 113-125.		0
93	2-deoxy-D-glucose encapsulated PLGA nanoparticles suppress hepatocellular carcinoma through cytotoxic effect and activation of antitumor immunity. <i>Journal of Hepatology</i> , 2020, 73, S641.	3.7	0
94	Iron loss-induced mitophagy via mitochondria ferritin suppresses NASH-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S686-S687.	3.7	0
95	Title is missing!. , 2020, 15, e0219412.		0
96	Title is missing!. , 2020, 15, e0219412.		0
97	Title is missing!. , 2020, 15, e0219412.		0
98	Title is missing!. , 2020, 15, e0219412.		0